Previous close | 0.3155 |
Open | 0.3300 |
Bid | 0.2918 x 100 |
Ask | 0.3251 x 100 |
Day's range | 0.2700 - 0.3322 |
52-week range | 0.2700 - 3.5300 |
Volume | |
Avg. volume | 1,190,645 |
Market cap | 19.445M |
Beta (5Y monthly) | 2.19 |
PE ratio (TTM) | N/A |
EPS (TTM) | -0.5800 |
Earnings date | 09 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 0.75 |
ROCKVILLE, Md., May 06, 2024--GlycoMimetics, Inc. (Nasdaq: GLYC), a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory diseases, today announced topline results from its Phase 3 global pivotal study of uproleselan in 388 patients with R/R AML. In the study, uproleselan combined with chemotherapy did not achieve a statistically significant improvement in overall survival in the intent to treat population versus chemothera
Just because a business does not make any money, does not mean that the stock will go down. For example, although...
ROCKVILLE, Md., April 25, 2024--GlycoMimetics, Inc. (Nasdaq: GLYC), today announced that it will host a conference call and webcast to report first quarter 2024 financial results on Thursday, May 9, 2024 at 8:30 a.m. ET.